TherapeuticsMD, Inc. — Q1 2024 Form 10-Q
Reporting period: Three months ended March 31, 2024. Financial amounts below are in U.S. dollars; financial statement figures are in thousands unless otherwise noted. TherapeuticsMD is now primarily a pharmaceutical royalty company, following its 2022 transition out of commercial operations. Legacy commercial results are presented as discontinued operations.
Financial performance and liquidity
| Metric | Q1 2024 | Q1 2023 |
|---|---|---|
| License and service revenue | $313 | $416 |
| Operating expenses | $1,455 | $3,083 |
| Operating loss | $(1,142) | $(2,667) |
| Other income, net | $333 | $357 |
| Continuing-operations net loss | $(809) | $(2,310) |
| Discontinued-operations income (loss) | $75 | $(1,293) |
| Net loss | $(734) | $(3,603) |
| Net loss per share, basic and diluted | $(0.06) | $(0.37) |
| Net cash used in continuing operating activities | $(229) | $(8,701) |
- Management attributed lower license revenue to changes in licensed-product sales. It reported approximately $295 of royalties as other income in Q1 2024.
- Cash and cash equivalents were $4,338 at March 31, 2024, versus $4,327 at year-end 2023. Total assets were $42,088 and total liabilities were $13,424.
- Current assets were $11,523 and current liabilities were $6,468. Royalty receivables totaled $21,077: $3,222 current and $17,855 long term.
- The balance sheet reports operating lease liabilities of $6,319 and no separate funded-debt line. Interest expense and other financing costs were zero in Q1 2024.
- Cash increased by $11 in the quarter. Continuing operations used $229 of cash; discontinued operations provided $240.
Material changes and business context
- Operating expenses fell 52.8% year over year, including a 56.7% reduction in selling, general and administrative expense, reflecting the smaller royalty-focused business.
- Continuing-operations net loss narrowed to $809 from $2,310. Net loss also improved, partly because discontinued operations recorded income of $75 versus a loss of $1,293 in Q1 2023.
- License and service revenue declined 24.8% to $313. Revenue came from Mayne Pharma, Theramex and Knight; the filing states that these partners accounted for 100% of license revenue.
- TherapeuticsMD’s Mayne agreement provides royalties generally at 8% on the first $80 million of annual U.S. net sales and 7.5% above that level, subject to adjustments. It also provides for minimum annual royalties of $3 million for 12 years, adjusted for inflation and subject to further adjustments, and sales-based milestone payments. Rates may decline to 2% for a product under specified patent or generic-entry conditions.
Outlook, risks and unusual items
- Going concern: Management states that substantial doubt exists about the company’s ability to continue as a going concern for the 12 months following issuance of the financial statements. Additional financing may be needed; failure to obtain it could force the company to curtail operations, sell assets or pursue a combination transaction. The statements contain no adjustments for a possible inability to continue as a going concern.
- Mayne working-capital dispute: In February 2024, Mayne’s calculation of payer-rebate and wholesale-distributor-fee allowances differed significantly from TherapeuticsMD’s estimate. The parties intend to use the agreement’s dispute process. The outcome and potential loss cannot be reasonably estimated, and no additional liability was accrued. Management says pending adjustments could be material.
- Management identifies slower or declining Mayne product sales, a higher-than-estimated working-capital settlement, unsuccessful financing and supply-chain issues as factors that could leave cash insufficient.
- The company has one full-time employee and relies on external consultants. Management assessed disclosure controls as effective at quarter-end and reported deployment of a new ERP system during Q1 2024.
- The filing gives no specific operating forecast or new quantitative guidance. It reports no material changes to risk factors since the 2023 Form 10-K.
Key facts for investors to verify
- Progress and resolution of the Mayne working-capital allowance dispute, including any resulting payment or recovery.
- Cash needs, available financing options and dilution risk, given the substantial-doubt going-concern disclosure and limited cash balance.
- Mayne product sales, royalty receipts and the collectability and timing of the substantial long-term royalty receivable.
- Whether partner commercialization—including Knight’s 2024 launch activity—supports royalty growth; the filing does not quantify partner-product sales.
- Potential effects of generic entry or patent outcomes on royalty rates, including the IMVEXXY litigation involving Teva, for which Mayne is responsible under the license agreement.